The analysis involves a comparison of the median (min–max) expression levels of WWOX and RUNX2 in Ewing sarcoma cases (n=7) versus controls (n=5), based on tissue protein levels assessed via immunohistochemistry. Here, RUNX2 is linked to Ewing sarcoma.